Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.96

-0.9%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (557)	3/30/2000 1:49:00 PM
From: scaram(o)uche	Read Replies (1) of 1834

PRODUCTS UNDER DEVELOPMENT The following table summarizes Neurocrine's most advanced products in research and clinical development. This table is qualified in its entirety by reference to the more detailed descriptions appearing elsewhere in this Form 10-K. ------------------------------------------------------------------------------ Program Indication Status* Commercial Rights ------------------------------------------------------------------------------ CRF Receptor Antagonist Anxiety/Depression Phase II Janssen/ Neurocrine GABA Receptor Subtype Insomnia Phase II Neurocrine Agonist IL-4 Fusion Toxin Glioblastoma Phase I/II Neurocrine Altered Peptide Ligand Multiple Sclerosis Phase II Neurocrine Altered Peptide Ligand Diabetes Phase I Neurocrine/ Taisho* GnRH Antagonist Endometriosis Development Neurocrine CRF Receptor Antagonist Anxiety/Depression Development Neurocrine Stroke <PAGE> Excitatory Amino Acid Neurodegenerative Research Wyeth-Ayerst / Transporters Diseases Neurocrine Melanocortin Receptor Obesity Research Neurocrine Antagonist Chemokine Antagonist Inflammatory Research Neurocrine Disorders Orexin Sleep Disorders Research Neurocrine Urocortin/CRF Agonist Obesity Research Lilly ---------- *Subject to exercise of Option Agreement by Taisho. See discussion of Strategic Alliances regarding Taisho on page 13. "Research" indicates identification and evaluation of compounds in in vitro and animal models. "Development" indicates that lead compounds have been discovered that meets certain in vitro and in vivo criteria. These compounds may undergo structural modification and more extensive evaluation prior to selection for preclinical development. "Phase I" indicates that Neurocrine and/or its collaborative partner is conducting clinical trials to determine safety, the maximally tolerated dose and pharmacokinetics of the compound in human volunteers. "Phase II" indicates that Neurocrine and/or its collaborative partner is conducting clinical trials in humans to determine safety and efficacy in an expanded patient population.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next